Horizon Financial Services’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Horizon Financial Services’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-12,005	Closed	-$22.2K	–	51
2023 Q1	$22.2K	Hold	12,005	–	–	0.02%	51
2022 Q4	$13.3K	Hold	12,005	–	–	0.01%	52
2022 Q3	$28K	Hold	12,005	–	–	0.02%	58
2022 Q2	$36K	Hold	12,005	–	–	0.03%	55
2022 Q1	$82K	Hold	12,005	–	–	0.05%	56
2021 Q4	$100K	Hold	12,005	–	–	0.06%	65
2021 Q3	$89K	Hold	12,005	–	–	0.06%	76
2021 Q2	$82K	Hold	12,005	–	–	0.06%	67
2021 Q1	$123K	Hold	12,005	–	–	0.11%	27
2020 Q4	$84K	Hold	12,005	–	–	0.08%	31
2020 Q3	$98K	Buy	+12,005	New	+$74.4K	0.1%	27

Other funds holding JNCE

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Horizon Financial Services's JNCE Position: Q2 2023 in Review

Horizon Financial Services sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 12,005 shares — an estimated $22.2K sold.

Horizon Financial Services first reported a position in JNCE in Q3 2020 and held it in 11 quarters. The position peaked at $123K in Q1 2021. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.

Horizon Financial Services reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Horizon Financial Services sold 12,005 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $22.2K.
Horizon Financial Services first reported a position in Jounce Therapeutics, Inc. Common Stock in Q3 2020 and held it in 11 quarters.
Horizon Financial Services's Jounce Therapeutics, Inc. Common Stock position peaked at $123K in Q1 2021.
1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Horizon Financial Services's 13F filing for Q2 2023, filed 20 Jul 2023.